A new docetaxel (D) gemcitabine (G) regimen as first-line chemotherapy in advanced non-small cell lung cancer (NSCLC): A phase II study.

被引：0
|
作者：
Morere, JF
Terrioux, P
Brechot, JM
Tredaniel, J
Bouchahda, M
Duhamel, JP
Mandet, J
Brain, E
Beerblock, K
Fellague, R
机构：
[1] Univ Paris 13, CHU Avicenne, Bobigny, France
[2] GERCOR, Paris, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：692S / 692S
页数：1
相关论文
共 50 条
  • [31] Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer
    Cappuzzo, F
    Novello, S
    De Marinis, F
    Franciosi, V
    Maur, M
    Ceribelli, A
    Lorusso, V
    Barbieri, F
    Castaldini, L
    Crucitta, E
    Marini, L
    Bartolini, S
    Scagliotti, GV
    Crinò, L
    BRITISH JOURNAL OF CANCER, 2005, 93 (01) : 29 - 34
  • [32] Phase I study of docetaxel in combination with gemcitabine as first line chemotherapy (CT) in patients with metastatic non-small cell lung cancer (NSCLC)
    Bildat, S
    Gatzemeier, U
    Reck, M
    Harstrick, A
    Eberhardt, W
    Achterrath, W
    Krauss, C
    Wilke, HJ
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S262 - S262
  • [33] Docetaxel and Oxaliplatin as First-Line Therapy for Advanced Non-Small Cell Lung Cancer: A Phase II Trial
    Radhakrishnan, A.
    Bitran, J. D.
    Milton, D. T.
    Tolzien, K.
    Hallmeyer, S.
    Nabhan, C.
    JOURNAL OF CHEMOTHERAPY, 2009, 21 (04) : 439 - 444
  • [34] Combination chemotherapy with carboplatin(CBDCA), docetaxel (DOC) and gemcitabine (GEM) in advanced non-small cell lung cancer (NSCLC). A phase II study
    Pectasides, D
    Aspropotamitis, A
    Halikia, A
    Visvikis, A
    Antoniou, F
    Kalantaridou, A
    Batzios, S
    Karvounis, N
    Athanassiou, A
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S263 - S263
  • [35] Biweekly docetaxel and carboplatin as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC). Finally results of a phase II study
    Firvida, J. L.
    Esquerdo, G.
    Amenedo, M.
    Salgado, M.
    LLorca, C.
    Perez, E.
    Cervera Grau, J.
    Ramos, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [36] Docetaxel in combination with Gemcitabine as first-line treatment of patients with inoperable, locally advanced or metastatic non-small cell lung cancer (NSCLC)
    Barata, Fernando
    Sousa, Amelia
    Camacho, Elvira
    Costa, Marco S.
    Canario, Dolores
    Nogueira, Fernando
    Semedo, Eulalia
    ANNALS OF ONCOLOGY, 2004, 15 : 179 - 179
  • [37] A phase II study of a modified cisplatin and Gemcitabine regimen in advanced non-small cell lung cancer (NSCLC): An ongoing study
    Gonzalez-Martin, A
    Garcia-Lopez, JL
    Crespo, C
    Lastra, E
    Pedraza, M
    Cerrato, L
    Rios, A
    Moyano, AJ
    Garrido, P
    ANNALS OF ONCOLOGY, 1998, 9 : 98 - 98
  • [38] Docetaxel and carboplatin as first-line therapy in advanced non-small cell lung carcinoma: A phase II study
    Jahanzeb, M
    Sarna, G
    Hirsch, R
    Radice, P
    Koletsky, A
    Martinez, M
    Kruglyak, E
    Wolin, E
    Camacho, E
    Kronish, L
    Motl, S
    ANTICANCER RESEARCH, 2004, 24 (2C) : 1239 - 1242
  • [39] Impact of gemcitabine (G) on the activity of first-line chemotherapy in non-small cell lung cancer (NSCLC): A meta-analysis.
    Pappagallo, G. L.
    Belvedere, O.
    Vinante, O.
    Grossi, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 398S - 398S
  • [40] Results of a phase II multicenter trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer
    Neubauer, MA
    Garfield, DH
    Kuerfler, PR
    Raju, RN
    Lindquist, DL
    Soo, EW
    Khan, M
    Boehm, KA
    Asmar, L
    LUNG CANCER, 2005, 47 (01) : 121 - 127
12345